,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,8800 HSC Parkway,Bryan,TX,77807-1107,United States,979 446 0027,https://www.ibioinc.com,Biotechnology,Healthcare,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.",105,"{'maxAge': 1, 'name': 'Dr. Martin B. Brenner D.V.M., Ph.D.', 'age': 51, 'title': 'CEO & Chief Scientific Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 578302, 'exercisedValue': 0, 'unexercisedValue': 0}",10,5,9,4,7,1693526400,1672444800,86400,4,0.3544,0.3455,0.325,0.358,0.3544,0.3455,0.325,0.358,0.0,-3.164246,-0.141,312518,312518,621196,749190,749190,0.3386,0.3399,3000,1300,7651935,0.26,11.0,15.334539,0.446,0.9019,0.0,0.0,USD,17819216,0.0,16634905,22612100,296667,471676,1690761600,1693440000,0.013099999,0.02202,0.10809,0.33,0.013099999,1.099,0.3079163,1656547200,1688083200,1680220800,-55557000,-160.14,-2.4,1:10,1528675200,35.71,-0.351,ASE,EQUITY,IBIO,IBIO,"iBio, Inc.","iBio, Inc.",1219152600,America/New_York,EDT,-14400000,0.3384,3.0,hold,6562000,0.391,-50825000,18428000,0.309,1.216,499000,105.975,0.049,-0.42455003,-1.14824,2167000,-43562624,-36969000,0.56713,0.0,-108.735466,USD,
1,8800 HSC Parkway,Bryan,TX,77807-1107,United States,979 446 0027,https://www.ibioinc.com,Biotechnology,Healthcare,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.",105,"{'maxAge': 1, 'name': 'Mr. Robert B. Kay', 'age': 82, 'title': 'Interim Sec. & Interim Treasurer', 'yearBorn': 1940, 'fiscalYear': 2022, 'totalPay': 92692, 'exercisedValue': 0, 'unexercisedValue': 0}",10,5,9,4,7,1693526400,1672444800,86400,4,0.3544,0.3455,0.325,0.358,0.3544,0.3455,0.325,0.358,0.0,-3.164246,-0.141,312518,312518,621196,749190,749190,0.3386,0.3399,3000,1300,7651935,0.26,11.0,15.334539,0.446,0.9019,0.0,0.0,USD,17819216,0.0,16634905,22612100,296667,471676,1690761600,1693440000,0.013099999,0.02202,0.10809,0.33,0.013099999,1.099,0.3079163,1656547200,1688083200,1680220800,-55557000,-160.14,-2.4,1:10,1528675200,35.71,-0.351,ASE,EQUITY,IBIO,IBIO,"iBio, Inc.","iBio, Inc.",1219152600,America/New_York,EDT,-14400000,0.3384,3.0,hold,6562000,0.391,-50825000,18428000,0.309,1.216,499000,105.975,0.049,-0.42455003,-1.14824,2167000,-43562624,-36969000,0.56713,0.0,-108.735466,USD,
2,8800 HSC Parkway,Bryan,TX,77807-1107,United States,979 446 0027,https://www.ibioinc.com,Biotechnology,Healthcare,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.",105,"{'maxAge': 1, 'name': 'Mr. Felipe  Duran', 'age': 42, 'title': 'Chief Financial Officer', 'yearBorn': 1980, 'exercisedValue': 0, 'unexercisedValue': 0}",10,5,9,4,7,1693526400,1672444800,86400,4,0.3544,0.3455,0.325,0.358,0.3544,0.3455,0.325,0.358,0.0,-3.164246,-0.141,312518,312518,621196,749190,749190,0.3386,0.3399,3000,1300,7651935,0.26,11.0,15.334539,0.446,0.9019,0.0,0.0,USD,17819216,0.0,16634905,22612100,296667,471676,1690761600,1693440000,0.013099999,0.02202,0.10809,0.33,0.013099999,1.099,0.3079163,1656547200,1688083200,1680220800,-55557000,-160.14,-2.4,1:10,1528675200,35.71,-0.351,ASE,EQUITY,IBIO,IBIO,"iBio, Inc.","iBio, Inc.",1219152600,America/New_York,EDT,-14400000,0.3384,3.0,hold,6562000,0.391,-50825000,18428000,0.309,1.216,499000,105.975,0.049,-0.42455003,-1.14824,2167000,-43562624,-36969000,0.56713,0.0,-108.735466,USD,
3,8800 HSC Parkway,Bryan,TX,77807-1107,United States,979 446 0027,https://www.ibioinc.com,Biotechnology,Healthcare,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.",105,"{'maxAge': 1, 'name': 'Stephen  Kilmer', 'title': 'Investor Relations Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",10,5,9,4,7,1693526400,1672444800,86400,4,0.3544,0.3455,0.325,0.358,0.3544,0.3455,0.325,0.358,0.0,-3.164246,-0.141,312518,312518,621196,749190,749190,0.3386,0.3399,3000,1300,7651935,0.26,11.0,15.334539,0.446,0.9019,0.0,0.0,USD,17819216,0.0,16634905,22612100,296667,471676,1690761600,1693440000,0.013099999,0.02202,0.10809,0.33,0.013099999,1.099,0.3079163,1656547200,1688083200,1680220800,-55557000,-160.14,-2.4,1:10,1528675200,35.71,-0.351,ASE,EQUITY,IBIO,IBIO,"iBio, Inc.","iBio, Inc.",1219152600,America/New_York,EDT,-14400000,0.3384,3.0,hold,6562000,0.391,-50825000,18428000,0.309,1.216,499000,105.975,0.049,-0.42455003,-1.14824,2167000,-43562624,-36969000,0.56713,0.0,-108.735466,USD,
4,8800 HSC Parkway,Bryan,TX,77807-1107,United States,979 446 0027,https://www.ibioinc.com,Biotechnology,Healthcare,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.",105,"{'maxAge': 1, 'name': 'Mr. Marc  Banjak J.D.', 'title': 'Gen. Counsel', 'exercisedValue': 0, 'unexercisedValue': 0}",10,5,9,4,7,1693526400,1672444800,86400,4,0.3544,0.3455,0.325,0.358,0.3544,0.3455,0.325,0.358,0.0,-3.164246,-0.141,312518,312518,621196,749190,749190,0.3386,0.3399,3000,1300,7651935,0.26,11.0,15.334539,0.446,0.9019,0.0,0.0,USD,17819216,0.0,16634905,22612100,296667,471676,1690761600,1693440000,0.013099999,0.02202,0.10809,0.33,0.013099999,1.099,0.3079163,1656547200,1688083200,1680220800,-55557000,-160.14,-2.4,1:10,1528675200,35.71,-0.351,ASE,EQUITY,IBIO,IBIO,"iBio, Inc.","iBio, Inc.",1219152600,America/New_York,EDT,-14400000,0.3384,3.0,hold,6562000,0.391,-50825000,18428000,0.309,1.216,499000,105.975,0.049,-0.42455003,-1.14824,2167000,-43562624,-36969000,0.56713,0.0,-108.735466,USD,
5,8800 HSC Parkway,Bryan,TX,77807-1107,United States,979 446 0027,https://www.ibioinc.com,Biotechnology,Healthcare,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.",105,"{'maxAge': 1, 'name': 'Ms. Lisa  Middlebrook', 'title': 'Chief HR Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",10,5,9,4,7,1693526400,1672444800,86400,4,0.3544,0.3455,0.325,0.358,0.3544,0.3455,0.325,0.358,0.0,-3.164246,-0.141,312518,312518,621196,749190,749190,0.3386,0.3399,3000,1300,7651935,0.26,11.0,15.334539,0.446,0.9019,0.0,0.0,USD,17819216,0.0,16634905,22612100,296667,471676,1690761600,1693440000,0.013099999,0.02202,0.10809,0.33,0.013099999,1.099,0.3079163,1656547200,1688083200,1680220800,-55557000,-160.14,-2.4,1:10,1528675200,35.71,-0.351,ASE,EQUITY,IBIO,IBIO,"iBio, Inc.","iBio, Inc.",1219152600,America/New_York,EDT,-14400000,0.3384,3.0,hold,6562000,0.391,-50825000,18428000,0.309,1.216,499000,105.975,0.049,-0.42455003,-1.14824,2167000,-43562624,-36969000,0.56713,0.0,-108.735466,USD,
